STUDYING THE EFFICACY OF TENOFOVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B

2014 ◽  
pp. 55-59
Author(s):  
Xuan Chuong Tran ◽  
Van Huy Tran
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load ◽  
Hbv Dna ◽  
University Hospital ◽  
Baseline Viral Load ◽  
Biochemical Response ◽  
Positive Chronic Hepatitis

Background: The HBeAg-positive chronic hepatitis B is the type of chronic hepatitis with active virus replication, has high viral load and difficult to treat. We evaluate the effects of treatment with tenofovir in HBeAg-positive chronic hepatitis B patients. Aims: Evaluate the treatment results in patients with HBeAg-positive chronic hepatitis B. Patients and methodes: HBeAg-positive chronic hepatitis B patients over 15 yrs treated at Hue University Hospital from Jan. 2012 to Dec. 2013. Results: Most of symptoms disappeared after 12 months. More than 85% patients have biochemical response. 81.8% patients have undetectable HBV DNA. Rate of HBV DNA decrease according to the baseline viral load. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Conclusions: Clinical and biochemical response were relatively high. 81.8% patients have undetectable HBV DNA. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Key words: HBeAg-positive chronic hepatitis B, HBV DNA

Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA =9 Log10 Copies/Ml)

2012 ◽  
Vol 142 (5) ◽  
pp. S-954
Author(s):  
Stuart C. Gordon ◽  
Patrick Marcellin ◽  
Zahary Krastev ◽  
Andrzej Horban ◽  
Jörg Petersen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tenofovir Disoproxil Fumarate ◽  
High Viral Load ◽  
Hbv Dna

Update in management of hepatitis B in pregnancy and prevention of mother to child hepatitis B transmission

2018 ◽  
Vol 1 (3) ◽  
pp. 1-8
Author(s):  
Naichaya Chamroonkul
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load ◽  
World Population ◽  
Hepatitis B Infection ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
Mother To Child

Even with two decades of widespread using hepatitis B vaccination, chronic hepatitis B remains a major global health problem. In Thailand, the prevalence of chronic hepatitis B infection was down from 8 - 10% in last decade to 5% recently. Failure to control mother to child transmission is one of the important barriers to the total elimination of hepatitis B infection from world population. In the majority, vertical transmission can be prevented with a universal screening program, immunoprophylaxis by administration of hepatitis B vaccine and hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load, the chance of immunoprophylaxis failure remains high. To date, there are standard recommendations by all international liver societies including AASLD, EASL and APASL suggest introducing an antiviral agent during the third trimester to CHB pregnant women with a high viral load. Previous US FDA pregnancy category B agents such as Tenofovir and Telbivudine are allowed through all trimesters of pregnancy and are effective for prevention of mother to child transmission. Breastfeeding for patients who receive antiviral agents can be allowed after a risk-benefit discussion with the patient and family.

scholarly journals Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Xiao-Jun Zhu ◽  
Xue-Hua Sun ◽  
Zheng-Hua Zhou ◽  
Shun-Qing Liu ◽  
Hua Lv ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Treatment Group ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Alanine Aminotransferase ◽  
Hbv Dna ◽  
Control Group ◽  
Hbeag Loss ◽  
Histological Improvement ◽  
Positive Chronic Hepatitis

Objective. To determine the efficacy and safety of Lingmao Formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase (ALT).Methods. 301 patients were randomly assigned to receive Lingmao Formula combined with entecavir (treatment group) or placebo combined with entecavir (control group) for 52 weeks. The outcomes of interest included the reduction of serum HBV DNA level, HBeAg loss, HBeAg seroconversion, ALT normalization, and histological improvement.Results. The mean decrease of serum HBV DNA level from baseline and the percentage of patients who had reduction in serum HBV DNA level ≥2 lg copies/mL in treatment group were significantly greater than that in control group (5.5 versus 5.4 lg copies/mL,P=0.010; 98.5% versus 92.6%,P=0.019). The percentage of HBeAg loss in treatment group was 22.8%, which was much higher than a percentage of 12.6% in control group (P=0.038). There was no significant difference between the two groups in histological improvement. Safety was similar in the two groups.Conclusions. The combination of Lingmao Formula with entecavir could result in significant decrease of serum HBV DNA and increase of HBeAg loss for HBeAg-positive chronic hepatitis B patients with mildly elevated ALT without any serious adverse events. Clinical trial registration number isChiCTR-TRC-09000594.

Comparison of the Efficacy of Entecavir and Tenofovir in Chronic Hepatitis B Patients With High Viral Load and/or High Fibrosis Scores at Week 48 of Therapy

2011 ◽  
Vol 140 (5) ◽  
pp. S-930-S-931 ◽  
Author(s):  
Ayse O. Kurdas Ovunc ◽  
Fatih Guzelbulut ◽  
Ebubekir Senates ◽  
Yasemin Gökden ◽  
Ayca G. Degirmenci Salturk ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load
Sign in / Sign up

Export Citation Format

Share Document